Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. (FABOLUS-FASTER)
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial
Sponsor: Insel Gruppe AG, University Hospital Bern
This PHASE4 trial investigates Coronary Artery Disease and STEMI - ST Elevation Myocardial Infarction and is currently completed. Insel Gruppe AG, University Hospital Bern leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE4
-
Nov 2018 — Aug 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Insel Gruppe AG, University Hospital Bern
For direct contact, visit the study record on ClinicalTrials.gov .